88.80 <%= Resources.Global.txtDown %>
Updated 21/03/2019
Change % -1.05% Stock price decreasing
Change -0.94 Stock price decreasing
Volume 311,495
High 90.74
Low 88.80
Open 89.94
ISIN BE0003818359
Prev close 89.74
# of shares 54.61M
Market cap 4,849.79M EUR

Market closed
Market is closed, opens at 08:00
Price development Latest 1 week 1 month 3 months 6 months 1 year
  88.80 2.3% Stock price increasing 2.9% Stock price increasing 10.1% Stock price increasing -8.2% Stock price decreasing 8.1% Stock price increasing
Powered by TradingView

News about Galapagos

  • English
  • Regulatory news

Company profile

Galapagos is a clinical-stage biotechnology company, involved in the discovery and development of small-molecule medicines. The company's product candidate portfolio includes Filgotinib, a JAK1 inhibitor to treat rheumatoid arthritis, Crohn's disease, and ulcerative colitis; novel therapies in cystic fibrosis (a chronic disease that affects the lungs and digestive system); GLPG1690, a selective autotaxin inhibitor with potential application in idiopathic pulmonary disease; GLPG1972 to treat osteoarthritis; and MOR106 to treat atopic dermatitis.

Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
23 March 2019 11:16:35
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20190320.1 - EUROWEB7 - 2019-03-23 12:16:35 - 2019-03-23 11:16:35 - 1000 - Website: OKAY